Business Wire

XPRIZE and Avanci Launch Partnership to Provide Innovators with IP and Licensing Expertise

22.10.2025 16:00:00 EEST | Business Wire | Press release

Share

XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s greatest challenges, and Avanci, the independent global leader in one-stop IP licensing platforms, today announced a partnership to empower XPRIZE innovators.

For more than three decades, XPRIZE competitions have ignited bold solutions that ripple far beyond the competition itself to transform industries, inspire new technologies, and build an extraordinary global ecosystem of innovators dedicated to problem solving. This partnership with Avanci ensures that XPRIZE teams and alumni have access to the expertise and resources they need to protect, scale, and amplify their impact in the real world through access to Avanci’s expertise and experience in intellectual property (IP) protection and licensing. Tailored support from Avanci will help those entrepreneurs protect their breakthrough innovations, navigate complex licensing landscapes, and position them for greater success.

“The impact of our work extends well beyond the conclusion of an XPRIZE competition - the competing teams’ impact continues to shape industries and improve lives long after a prize is awarded,” said Anousheh Ansari, CEO, XPRIZE. “Our innovators have generated more than 9,700 patents and counting for work that’s driving real change across the globe. With Avanci’s expertise, we’re helping them protect and scale those breakthroughs to deliver lasting impact in every sector.”

Kasim Alfalahi, Founder and CEO of Avanci, added: “We’re inspired by XPRIZE’s mission to solve humanity’s greatest challenges through innovation. Our team brings decades of senior IP and licensing experience at many of the world’s leading companies across industries. By engaging early in the creative process, we can empower innovators to protect and scale their solutions for maximum impact. Our organizations complement one another perfectly. Together, we can help innovators realize their vision for a better world.”

Avanci has advised several XPRIZE teams across six different XPRIZE competitions, including participants in the recently awarded XPRIZE Rainforest competition. One notable example is how the company provided support to Map of Life Solutions (MOL), who won $2 million as one of the leading teams in demonstrating the most innovative technology for exploring Earth’s biodiversity.

As Map of Life Solutions aims to commercialize its biodiversity intelligence platform and expand access to scalable biodiversity measurement tools, they came to Avanci with complex questions around intellectual property and data licensing for foundational global biodiversity datasets. Avanci supported them by providing legal and strategic guidance to clarify data-use rights and assess IP protection options.

“Avanci’s support helped us navigate one of the most critical steps in turning a global biodiversity science platform into a viable business,” said Chrissy Durkin, CCO of Map of Life Solutions. “Their expertise gave us the confidence that our data-driven innovation could scale responsibly—protecting both our technology and the integrity of the science behind it.”

Avanci also supported XPRIZE Carbon Removal competitor, BIOSORRA, a company focused on biochar carbon removal solutions, aiming to build a robust IP strategy that protects their scientific and technological innovations, while supporting company scalability, business goals, and the positive impact of their work.

"We leveraged Avanci’s expertise to strengthen BIOSORRA’s intellectual property framework, ensuring it evolves alongside our growth, safeguards our technological advancements all towards enhancing brand reputation, and reinforces our mission-driven innovation,” said Inés Serra Baucells, Co-Founder and CEO, BIOSORRA.

The next phase of the Avanci and XPRIZE partnership is to develop tools to protect and support IP that can be shared across XPRIZE’s Alumni Network of 650 teams.

The partnership announcement comes ahead of XPRIZE’s annual Visioneering event taking place in Malibu, California October 23-25, 2025, where leaders from around the world convene to explore future prize concepts. Avanci will be a sponsor of the event and will join a panel discussion to share insights and early learnings from supporting XPRIZE teams through this new collaboration.

About XPRIZE

XPRIZE is the recognized global leader in designing and executing large-scale competitions to solve humanity’s greatest challenges. For over 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future. Donate, learn more, and co-architect a world of abundance with us at xprize.org.

About Avanci

Avanci believes that sharing patented technology can be simpler. A global independent intermediary not owned or controlled by licensors or licensees, Avanci works at the intersection of different industries. Our one-stop solutions are designed to bring efficiency, convenience, and predictability to the licensing process. Since 2016, Avanci has been driving innovation forward by making connections through our licensing platforms. www.avanci.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251022512362/en/

Contacts

Media contact:
Caitlin Chase
Senior Director of Communications
Caitlin.chase@xprize.org
210-386-1785

Ryan Peal
Senior Vice President, Marketing & Communications
media@avanci.com
310-490-1915

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye